Evidence map›Paper›PMID 40750916›Full record

ArticleCommunications chemistry2025

A bottom-up approach to find lead compounds in expansive chemical spaces.

Álvaro Serrano-Morrás, Andrea Bertran-Mostazo, Marina Miñarro-Lleonar, Arnau Comajuncosa-Creus, Adrià Cabello, Carme Labranya, Carmen Escudero, Tian V Tian, Inna Khutorianska, Dmytro S Radchenko and 10 more

Abstract read
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Strategies for Identifying Molecules of Interest in Large Chemical Spaces.Journal of chemical information and modeling · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Representative Random Sampling of Chemical Space.Journal of chemical theory and computation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Álvaro Serrano-Morrás *Unitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.
Andrea Bertran-Mostazo *Unitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-7971-6540
Marina Miñarro-LleonarUnitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.
Arnau Comajuncosa-CreusInstitut de Recerca Biomèdica (IRB Barcelona) and Barcelona Institute of Science and Technology (BIST). c/ Baldiri i Reixac, C\ Baldiri i Reixac, 10-12, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9633-7665
Adrià CabelloUnitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8338-1835
Carme LabranyaUnitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.
Carmen EscuderoUpper Gastrointestinal and Endocrine Tumor Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Nazaret 115-117, 08035, Barcelona, Spain.
Tian V TianUpper Gastrointestinal and Endocrine Tumor Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Nazaret 115-117, 08035, Barcelona, Spain.
Inna KhutorianskaEnamine Ltd., 78 Winston Churchill St., 02094, Kyїv, Ukraine.
Dmytro S RadchenkoEnamine Ltd., 78 Winston Churchill St., 02094, Kyїv, Ukraine.ORCID http://orcid.org/0000-0001-5444-7754
Yurii S MorozEnamine Ltd., 78 Winston Churchill St., 02094, Kyїv, Ukraine.
Lucas DefelipeEuropean Molecular Biology Laboratory, Building 25a, DESY, 22607, Hamburg, Germany.ORCID http://orcid.org/0000-0001-7859-7300
David Ruiz-CarrilloEuropean Molecular Biology Laboratory, Building 25a, DESY, 22607, Hamburg, Germany.
Maria Garcia-AlaiEuropean Molecular Biology Laboratory, Building 25a, DESY, 22607, Hamburg, Germany.ORCID http://orcid.org/0000-0002-5200-7816
Robert SchmidtCenter for Bioinformatics, University of Hamburg ZBH, Albert-Einstein-Ring 8-10, 22761, Hamburg, Germany.
Matthias RareyCenter for Bioinformatics, University of Hamburg ZBH, Albert-Einstein-Ring 8-10, 22761, Hamburg, Germany.ORCID http://orcid.org/0000-0002-9553-6531
Patrick AloyInstitut de Recerca Biomèdica (IRB Barcelona) and Barcelona Institute of Science and Technology (BIST). c/ Baldiri i Reixac, C\ Baldiri i Reixac, 10-12, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-3557-0236
Carles GaldeanoUnitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1702-0369
Jordi Juárez-JiménezUnitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain. jordi.juarez@ub.edu.ORCID http://orcid.org/0000-0003-1464-1397
Xavier BarrilUnitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacéutica, i Fisicoquímica. Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028, Barcelona, Spain. xbarril@me.com.ORCID http://orcid.org/0000-0002-0281-1347

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug discovery starts with the identification of a "hit" compound that, following a long and expensive optimization process, evolves into a drug candidate. Bigger screening collections increase the odds of finding more and better hits. For this reason, large pharmaceutical companies have invested heavily in high-throughput screening (HTS) collections that can contain several million compounds. However, this figure pales in comparison with the emergent on-demand chemical collections, which have recently reached the trillion scale. These chemical collections are potentially transformative for drug discovery, as they could deliver many diverse and high-quality hits, even reaching lead-like starting points. But first, it will be necessary to develop computational tools capable of efficiently navigating such massive virtual collections. To address this challenge, we have conceived an innovative strategy that explores the chemical universe from the bottom up, performing a systematic search on the fragment space (exploration phase), to then mine the most promising areas of on-demand collections (exploitation phase). Using a hierarchy of increasingly sophisticated computational methods to remove false positives, we maximize the success probability and minimize the overall computational cost. A basic implementation of the concept has enabled us to validate the strategy prospectively, allowing the identification of new BRD4 (BD1) binders with potencies comparable to stablished drug candidates.

Identifiers

PMID40750916
PMCPMC12316891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.